Ocular Therapeutix shares surge 10.10% after-hours as company plans NDA submission for wet AMD treatment based on Phase 3 data.

Ocular Therapeutix surged 10.10% in after-hours trading following its announcement to submit a new drug application (NDA) for AXPAXLI, its wet age-related macular degeneration treatment, based on Phase 3 trial data. The company cited year 1 results from the SOL-1 trial as the basis for the NDA, with top-line data expected in Q1 2026 and regulatory engagement planned with the FDA. This milestone signals progress toward potential commercialization of AXPAXLI, a key product candidate in Ocular’s retina-focused pipeline. While the firm also disclosed inducement grants for new employees, this equity-related activity is less likely to drive significant stock movement compared to the regulatory advancement. The NDA filing, perceived as a catalyst for future revenue growth, directly aligns with the sharp after-hours price increase.